Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe

Metabolism: Clinical and Experimental

Volumn 59, Issue 6, 2010, Pages 921-926

  Kater, Ana Lucia de Almeida ^a   Batista, Marcelo Costa ^a   Ferreira, Sandra Roberta Gouvea ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALBUMIN; APOLIPOPROTEIN B; CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EZETIMIBE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM; FEMALE; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

ADOLESCENT; ADULT; AGED; ANTHROPOMETRY; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD GLUCOSE; BODY MASS INDEX; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; PREDIABETIC STATE; SIMVASTATIN; YOUNG ADULT;

EID: 77952292502     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.02.011     Document Type: Article

References (41)

1. Han S.H., Quon M.J., and Koh K.K. Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Opin Lipidol 18 (2007) 58-65
2. Sjöholm A., and Nyström T. Endothelial inflammation in insulin resistance. Lancet 365 (2005) 610-612
3. Devaraj S., Siegel D., and Jialal I. Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol 100 (2007) 1397-1399
4. Devaraj S., Chan E., and Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 91 (2006) 4489-4496
5. Festa A., D'Agostino Jr. R., Howard G., et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
6. Huptas S., Geiss H.C., Otto C., and Parhofer K.G. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol 98 (2006) 66-69
7. Fogari R., Preti P., Zoppi A., et al. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur J Clin Pharmacol 62 (2006) 817-822
8. Okada K., Maeda N., Kikuchi K., et al. Pravastatin improves insulin resistance in dyslipidemic patients. J Atheroscler Thromb 12 (2005) 322-329
9. Paolisso G., Barbagallo M., Petrella G., et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 150 (2000) 121-127
10. Ishikawa M., Namiki A., Kubota T., et al. Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. Intern Med 45 (2006) 51-55
11. Dagli N., Yavuzkir M., and Karaca I. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 30 (2007) 230-235
12. ter Avest E., Abbink E.J., de Graaf J., et al. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest 35 (2005) 558-564
13. Bulcão C., Giuffrida F.M., Ribeiro-Filho F.F., and Ferreira S.R. Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity?. Braz J Med Biol Res 40 (2007) 229-235
14. Chu C.H., Lee J.K., Lam H.C., et al. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes. J Endocrinol Invest 31 (2008) 42-47
15. Forst T., Pfützner A., Lübben G., et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism 56 (2007) 491-496
16. Spranger J., Kroke A., Möhlig M., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 361 (2003) 226-228 [Erratum in: Lancet 2002;361:1060.]
17. Gouni-Berthold I., Berthold H.K., Chamberland J.P., Krone W., and Mantzoros C.S. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf) 68 (2008) 536-541
18. Blanco-Colio L.M., Martín-Ventura J.L., Gómez-Guerrero C., et al. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. Eur J Pharmacol 586 (2008) 259-265
19. Davidson M.H., McGarry T., Bettis R., et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40 (2002) 2125-2134
20. Ballantyne C.M., Houri J., Notarbartolo A., et al., Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107 (2003) 2409-2415
21. Halcox J.P., and Deanfield J.E. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 109 Suppl 1 (2004) II42-II48
22. Juhan-Vague I., Alessi M.C., Mavri A., and Morange P.E. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1 (2003) 1575-1579
23. Blanco-Colio L.M., Martín-Ventura J.L., de Teresa E., et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J 153 (2007) 881-888
24. Meredith I.T., Plunkett J.C., Worthley S.G., Hope S.A., and Cameron J.D. Systemic inflammatory markers in acute coronary syndrome: association with cardiovascular risk factors and effect of early lipid lowering. Coron Artery Dis 16 (2005) 415-422
25. Douglas K., O'Malley P.G., and Jackson J.L. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 145 (2006) 117-124
26. Mann J.F., Yi Q.L., and Gerstein H.C. Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int 66 (2004) S59-S62
27. Hillege H.L., Fidler V., Diercks G.F., et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106 (2002) 1777-1782
28. Ray K.K., Morrow D.A., Shui A., Rifai N., and Cannon C.P. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22). Am J Cardiol 98 (2006) 861-865
29. Sejda T., Jedlièková V., Svandová E., and Poledne R. The effect of fluvastatin on cICAM-1 as a biomarker of endothelial dysfunction in patients with dyslipidemia. Int Angiol 25 (2006) 414-417
30. Hogue J.C., Lamarche B., Tremblay A.J., et al. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 57 (2008) 380-386
31. Tonolo G., Melis M.G., Formato M., et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 30 (2000) 980-987
32. Wei J.L., Cui H.M., and Ma C.Y. Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome. Eur J Med Res 12 (2007) 216-221
33. Laumen H., Skurk T., and Hauner H. The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis 196 (2008) 565-573
34. Hanefeld M., Marx N., Pfützner A., et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 49 (2007) 290-297
35. Nishino M., Hoshida S., Kato H., et al. Preprocedural statin administration can reduce thrombotic reaction after stent implantation. Circ J 72 (2008) 232-237
36. Matsuda M., and DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22 (1999) 1462-1470
37. Ridker P.M. Evaluating novel cardiovascular risk factors: can we better predict heart attacks?. Ann Intern Med 130 (1999) 933-937
38. Kastelein J.J., Akdim F., Stroes E.S., Zwinderman A.H., Bots M.L., Stalenhoef A.F., et al., ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443 Erratum in: N Engl J Med. 2008; 358:1977
39. Meigs J.B., Hu F.B., Rifai N., and Manson J.E. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 291 (2004) 1978-1986
40. Festa A., Williams K., Tracy R.P., Wagenknecht L.E., and Haffner S.M. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 113 (2006) 1753-1759
41. Donnelly R., Yeung J.M., and Manning G. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes. J Hypertens Suppl 21 (2003) S7-S12